An observational study in Pulmonary Emphysema, sponsored by Pulmonx Corporation. Completed at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-15.
Sponsored by Pulmonx Corporation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Pulmonary Emphysema with a site in Germany — 3 open to participants now, 3 under way, 1 of them phase 3. Pulmonary Emphysema · Germany.
Among the 14 studies in Pulmonary Emphysema with a site in Germany, this one is the only one that started in 2020, is one of 6 observational ones, and was the 11th registered.
64 studies on the registry are indexed under Pulmonary Emphysema; 7 are open to participants now.
Browse Pulmonary Emphysema studies →3 of the 14 studies in Pulmonary Emphysema with a site in Germany are open now. Recruiting first, the newest first:
Grifols Therapeutics LLC · Sites in Germany, United States, Denmark and 6 more countries
Ages 18–80
Morair Medtech, LLC · Sites in Germany, Austria, Netherlands
Ages 40+
Pulmonx Corporation · Sites in Germany, United States, Australia and 7 more countries
Ages 40–80
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 6 Pulmonary Emphysema studies recruiting now, 3 set no upper age limit and 1 stops at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 3 · Phase 4 1
First in 2009; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2 is below the median of 98 across 14 observational studies indexed under Pulmonary Emphysema.
Median enrollment 58 across the 8 interventional studies, 88 across the 6 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 8 most frequent:
Pulmonx Corporation is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Pulmonx Corporation has 3 studies filed under Pulmonary Emphysema — fewer than ten, so there is no comparison to draw.
2 of the studies in Pulmonary Emphysema with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
| NCT06035120Pulmonx CorporationAn Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Pulmonary Emphysema with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Post-Market Evaluation of the Zephyr Valve 5.5-LP EBV to assess Treated Lobar Volume Reduction (TLVR), changes in lung function and the safety profile of the Zephyr Valve treatment with the use of at least one Zephyr Valve 5.5-LP EBV.
This is a multi-center, single-arm, prospective, observational study. Approximately 70 study participants undergoing Zephyr Valve treatment with the use of at least one Zephyr Valve 5.5-LP EBV will be enrolled and followed out to 3 months. Assessments will be conducted at 45 days and 3 months. The evaluation will be conducted at up to 6 sites.
Patients prescribed Zephyr Valve treatment for their emphysema will be consented and will be enrolled only after: 1) determination of little to no collateral ventilation between target and ipsilateral lobes and 2) implantation of at least one Zephyr Valve 5.5-LP EBV. Baseline data will be collected retrospectively after enrollment of a patient in the Post-Market Evaluation. Performance and safety of the Zephyr Valve treatment with the use of at least one Zephyr Valve 5.5-LP will be evaluated post-treatment based on data collected until 3 months after the treatment.
The population evaluated will comprise of patients with hyperinflation associated with severe emphysema that are considered appropriate for the procedure by their physician, confirmed to have little to no collateral ventilation and had at least one Zephyr Valve 5.5-LP EBV implanted during the procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients undergoing Zephyr Valve treatment with the use of at least one Zephyr Valve 5.5-LP EBV.
Device: The Pulmonx Zephyr Endobronchial Valve (EBV) 5.5- LP
The Zephyr Valves are implantable bronchial valves intended to control airflow in order to improve lung function in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks.
Treated Lobar Volume Reduction (TLVR) responders
The percentage of patients treated with the Zephyr Valve 5.5-LP EBV who achieved a Treated Lobar Volume Reduction (TLVR) of the treated lobe (s) of ≥350ml as seen via HRCT at 45-days.
Time frame: 45 days
Treated Lobar Volume Reduction (TLVR) changes from Baseline
Treated Lobar Volume Reduction (TLVR) as seen via HRCT at 45-days (absolute and percent changes from baseline).
Time frame: 45 days
Lobar occlusion
Lobar occlusion of the treated lobe at 45-days post-procedure as visualized by HRCT.
Time frame: 45 days
Post-Bronchodilator Forced Expiratory Volume in 1 second (FEV1)
Post-Bronchodilator Forced Expiratory Volume in 1 second (FEV1) at 3-months (absolute and percent changes from baseline).
Time frame: 3 months
Residual Volume (RV)
Residual Volume at 3 months, when available (absolute and percent changes from baseline).
Time frame: 3 months
Total Lung Capacity
Total Lung Capacity (TLC) at 3 months, when available (absolute and percent changes from baseline).
Time frame: 3 months
Inspiratory Capacity
Inspiratory Capacity (IC) at 3 months, when available (absolute and percent changes from baseline).
Time frame: 3 months
Residual Volume/Total Lung Capacity (RV/TLC)
RV/TLC ratio at 3 months, when available (absolute and percent changes from baseline).
Time frame: 3 months
Inspiratory Capacity/Total Lung Capacity (IC/TLC)
IC/TLC ratio at 3 months, when available (absolute and percent changes from baseline).
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2020 to primary completion in Aug 2021, 18 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonx Corporation